<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03690713</url>
  </required_header>
  <id_info>
    <org_study_id>NCT186918690001</org_study_id>
    <nct_id>NCT03690713</nct_id>
  </id_info>
  <brief_title>International Collaboration of Comprehensive Physiologic Assessment</brief_title>
  <official_title>International Patient-level Pooled Analysis of Comprehensive Physiologic Assessment: Collaborating Project of Korea, Japan, and Spain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tsuchiura Kyodo General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital San Carlos, Madrid</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Imperial College Healthcare NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tokyo Medical and Dental University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sungkyunkwan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Inje University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Keimyung University Dongsan Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ulsan University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current study evaluated prognostic implication of comprehensive physiologic assessment
      using fractional flow reserve, coronary flow reserve (CFR) and index of microcirculatory
      resistance (IMR).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The patient-level data was gathered from 3 nations (Korea, Japan, Spain). The total 1397
      patients (1694 vessels) data was collected from 5 university hospitals in Korea (Seoul
      National University Hospital, Samsung Medical Centre, Inje University Ilsan Paik Hospital,
      Keimyung University Dongsan Medical Centre, and Ulsan University Hospital, Korea) and
      Tsuchiura Kyodo General Hospital, Ibaraki, Japan, and Hospital Clinico San Carlos, Madrid,
      Spain.

      Standardized form of data collection sheet was used and all study adopted standardized
      definition of patient's baseline characteristics, clinical outcomes, and physiologic data. In
      case of acute coronary syndrome (unstable angina, non-ST-segment elevation myocardial
      infarction, and ST-segment elevation myocardial infarction), only non-culprit vessel was
      included in the data.

      Primary outcome is patient- and vessel-oriented composite outcome at 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2018</start_date>
  <completion_date type="Actual">September 26, 2018</completion_date>
  <primary_completion_date type="Actual">June 1, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative incidence of a composite of any death, any myocardial infarction, or any ischemia-driven revascularization</measure>
    <time_frame>5 year</time_frame>
    <description>Patient-oriented composite outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cumulative incidence of a composite of cardiac death, target-vessel related myocardial infarction, or target-vessel revascularization</measure>
    <time_frame>5 year</time_frame>
    <description>Vessel-oriented composite outcome</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of any death</measure>
    <time_frame>5 year</time_frame>
    <description>all-cause mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of cardiac death</measure>
    <time_frame>5 year</time_frame>
    <description>cardiac death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of myocardial infarction</measure>
    <time_frame>5 year</time_frame>
    <description>MI was defined as elevated cardiac enzyme levels greater than the upper limit of the normal range with either ischemic symptoms or electrocardiography changes indicating ischemia after index procedure. Periprocedural MI was not included as a clinical outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of ischemia-driven revascularization</measure>
    <time_frame>5 year</time_frame>
    <description>Ischemia-driven revascularization was defined as a revascularization procedure with at least one of the following: (1) recurrence of angina; (2) positive non-invasive test; and (3) positive invasive physiologic test</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">1397</enrollment>
  <condition>Stable Angina</condition>
  <condition>Unstable Angina</condition>
  <condition>Non-ST Elevation Myocardial Infarction</condition>
  <condition>ST-segment Elevation Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Patient and Vessels underwent physiologic evaluation</arm_group_label>
    <description>The total 1397 patients (1694 vessels) which evaluated using pressure-temperature sensor wire and measured FFR, CFR, and IMR.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Fractional flow reserve, coronary flow reserve, and index of microcirculatory resistance</intervention_name>
    <description>The pressure sensor was positioned at the distal segment of a target vessel, and intracoronary nitrate was administered before each physiologic measurement. To derive resting mean transit time (Tmn), a thermodilution curve was obtained by using 3 injections (3-4 mL each) of room-temperature saline. Hyperemic proximal aortic pressure (Pa), distal arterial pressure (Pd), and hyperemic Tmn were measured during sustained hyperemia. CFR was calculated as resting Tmn/hyperemic Tmn. FFR was calculated as the lowest average of 3 consecutive beats during hyperemia. The uncorrected IMR was calculated by Pd × Tmn during hyperaemia. All IMR values were corrected by Yong's formula (Pa × Tmn × ([1.35 × Pd/Pa] − 0.32).</description>
    <arm_group_label>Patient and Vessels underwent physiologic evaluation</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients who underwent clinically indicated invasive coronary angiography and measurements
        of FFR, CFR, and IMR for at least 1 coronary artery
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - patients who underwent clinically indicated invasive coronary angiography and
        measurements of FFR, CFR, and IMR for at least 1 coronary artery

        Exclusion Criteria:

          -  Patients with hemodynamic instability

          -  left ventricular dysfunction

          -  culprit vessel of acute coronary syndrome
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Bon-Kwon Koo, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Javier Escaned, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Clinico San Carlos, Madrid, Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tsunekazu Kakuta, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Tokyo Medical and Dental University, Tokyo, Japan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joo Myung Lee, MD, MPH, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Samsung Medical Center, Seoul, Korea</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tokyo Medical and Dental University</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos, Madrid, Spain</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>September 26, 2018</study_first_submitted>
  <study_first_submitted_qc>September 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2018</study_first_posted>
  <last_update_submitted>September 28, 2018</last_update_submitted>
  <last_update_submitted_qc>September 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Bon-Kwon Koo</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>fractional flow reserve</keyword>
  <keyword>myocardial ischemia</keyword>
  <keyword>coronary artery disease</keyword>
  <keyword>coronary flow reserve</keyword>
  <keyword>index of microcirculatory resistance</keyword>
  <keyword>prognosis</keyword>
  <keyword>percutaneous coronary intervention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Angina Pectoris</mesh_term>
    <mesh_term>Angina, Stable</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
    <mesh_term>Angina, Unstable</mesh_term>
    <mesh_term>Non-ST Elevated Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Anonymized patient level data will be made available by the corresponding author for reasonable requests. Consent was not obtained for data sharing but the presented data are anonymized and risk of identification is minimal.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

